Description: Our understanding of the biology of aging is increasing rapidly, creating insight into how and why any organism is aging. Some of the mechanisms by which the process of aging occurs in mammals are sufficiently well understood that clinical trials targeting them in humans to improve later life health and longevity are now being undertaken. Translating results seen in mammals to humans has the potential to increase life expectancy far beyond what we have seen historically. Come explore the current state and outlook of research.

Description: The presenters will provide an overview of the current state of the Group Life product space.

Description: A discussion of some of the economic advantages of Offshore Life Reinsurance

Description: “Getting to Woe Some” is a thought-provoking title for Rick Flaspöhler’s recent presentation to the ACLI Reinsurance Executive Round Table in March 2005. Flaspöhler presented the high-level findings of the biennial reinsurance survey, and in his words this industry has gone from “bad to worse.” The reinsurance industry now finds itself in a unique and difficult situation that will require dramatic steps to improve things going forward.

Description: Chairperson's Corner from the March 2004 issue of Reinsurance News.

Description: Feature article discussing what’s to transpire at the upcoming Canadian reinsurers industry meeting.

Description: This article describes the common uses , reinsurance structures , advantages , and risk- based capital repercussions of utilizing a captive to accept health care risks .

Description: Feature article describing the benefits of attending the ReFocus meeting.

Description: Read the March 2020 issue of Reinsurance News published by the Reinsurance Section. Newsletters provide practical information for the working actuary, articles on trends that impact sections and news about section activities.

Description: This three-part series provides an overview of the rapidly evolving and dynamic gene and cellular therapy landscape, from the clinical, historical, and risk transfer perspectives. It covers the actuarial considerations in pricing cell and gene insurance and reinsurance, the value assessment of the therapies, manufacturer pricing, and reinsurance cost.